Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy.

Mao RC, Yin YK, Qin YL, Wu XH, Weng XH, Zhang JM, Lu M.

Hepatol Res. 2009 Jan;39(1):14-20. doi: 10.1111/j.1872-034X.2008.00411.x.

PMID:
19125938
2.

Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.

Amini-Bavil-Olyaee S, Herbers U, Luedde T, Trautwein C, Tacke F.

J Viral Hepat. 2011 Nov;18(11):804-14. doi: 10.1111/j.1365-2893.2010.01378.x. Epub 2010 Sep 30.

PMID:
20887378
3.

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.

Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.

Antivir Ther. 2012;17(4):701-9. doi: 10.3851/IMP2074. Epub 2012 Feb 23.

PMID:
22358132
4.

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.

Zhang Y, He S, Li QL, Guo JJ.

Virus Res. 2013 Nov 6;177(2):156-62. doi: 10.1016/j.virusres.2013.08.003. Epub 2013 Aug 19.

PMID:
23968804
5.

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.

Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.

6.
7.

Successful treatment of an entecavir-resistant hepatitis B virus variant.

Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K.

J Med Virol. 2007 Dec;79(12):1811-7.

PMID:
17935165
8.

Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.

Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY.

J Med Virol. 2013 Jan;85(1):55-64. doi: 10.1002/jmv.23440. Epub 2012 Oct 23.

PMID:
23096938
9.

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.

Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.

Antivir Ther. 2004 Jun;9(3):353-63.

PMID:
15259898
10.
11.

[Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].

Liang PP, Guo JJ, Li QL, Luo Q, Shi XF, Huang AL.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jul;19(7):516-20. doi: 10.3760/cma.j.issn.1007-3418.2011.07.012. Chinese.

PMID:
22152243
12.

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy.

Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Hua T, Sui S, Lu F, Duan Z.

Exp Ther Med. 2016 Jan;11(1):117-123. Epub 2015 Nov 12.

13.

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.

Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY.

Antivir Ther. 2009;14(7):985-93. doi: 10.3851/IMP1417.

PMID:
19918102
14.

Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.

Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.

Scand J Gastroenterol. 2011 Sep;46(9):1111-7. doi: 10.3109/00365521.2011.584898. Epub 2011 May 30.

PMID:
21623676
15.

[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].

Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.

Zhonghua Gan Zang Bing Za Zhi. 2011 Nov;19(11):828-32. doi: 10.3760/cma.j.issn.1007-3418.2011.11.009. Chinese.

PMID:
22433304
16.

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.

J Viral Hepat. 2012 Mar;19(3):213-9. doi: 10.1111/j.1365-2893.2011.01533.x. Epub 2011 Oct 17.

PMID:
22329376
17.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
18.

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.

Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.

Hepatology. 2009 Oct;50(4):1064-71. doi: 10.1002/hep.23145.

PMID:
19637288
19.

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.

Karatayli E, Idilman R, Karatayli SC, Cevik E, Yakut M, Seven G, Kabaçam G, Bozdayi AM, Yurdaydin C.

Antivir Ther. 2013;18(1):77-85. doi: 10.3851/IMP2294. Epub 2012 Aug 10.

PMID:
22878399
20.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.

Gastroenterology. 2012 Sep;143(3):619-28.e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27.

PMID:
22643350

Supplemental Content

Support Center